Stocktoria
Grace Therapeutics, Inc. GRCE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-03-07
Grace Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100.0M |
| R&D expense | $2.4M | $9.5M | $4.7M | $10.0M | $5.6M |
| Operating income | -$11.1M | -$16.7M | -$12.9M | -$52.2M | -$15.6M |
| Income tax | -$1.7M | -$3.2M | -$1.8M | -$9.5M | -$648,000 |
| Net income | -$7.8M | -$9.6M | -$12.9M | -$42.4M | -$9.8M |
| EPS (diluted) | $-0.47 | $-0.79 | $-1.35 | $-5.71 | $-0.27 |
| Operating cash flow | -$8.9M | -$14.9M | -$12.3M | -$15.9M | -$17.2M |
| Cash & equivalents | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M |
| Total liabilities | $2.8M | $5.4M | $11.6M | $11.2M | $20.4M |
| Shareholders' equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M |
Source: SEC EDGAR filings · CIK 0001444192 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.